Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.
- Published In:
- Anti-cancer agents in medicinal chemistry, 10(10), 753-68 (2010)
- Authors:
- Mas-Moruno, Carlos, Rechenmacher, Florian, Kessler, Horst(4)
- Database ID:
- RPEP-01659
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01659APA
Mas-Moruno, Carlos; Rechenmacher, Florian; Kessler, Horst. (2010). Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.. Anti-cancer agents in medicinal chemistry, 10(10), 753-68.
MLA
Mas-Moruno, Carlos, et al. "Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.." Anti-cancer agents in medicinal chemistry, 2010.
RethinkPeptides
RethinkPeptides Research Database. "Cilengitide: the first anti-angiogenic small molecule drug c..." RPEP-01659. Retrieved from https://rethinkpeptides.com/research/mas-moruno-2010-cilengitide-the-first-antiangiogenic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.